Omixon

Omixon is a global transplantation diagnostic company with a mission to provide histocompatibility laboratories with innovative technologies to improve transplant outcomes. Omixon is headquartered in Budapest, Hungary, with operations in the United States, Brazil and the Netherlands serving more than 100 laboratories worldwide. Building on multidisciplinary competences in bioinformatics, software engineering, molecular biology and regulatory science, Omixon transforms molecular biology innovations into state-of-the-art products in transplant diagnostics.

Omixon was the first to successfully introduce NGS-based HLA typing kit and software Holotype HLA, and HLA Twin in 2014. Omixon was the first to release a high-resolution HLA genotyping product NanoTYPE, a nanopore-based  long-read sequencing technology with less than 5h turnaround time, complemented by NanoTYPER™ software. Omixon is the first to bring to market the first donor-derived cell-free DNA kit HoloGRAFT.